New recruitment to increase Qlucore's sales.

Nasdaq First North-listed Qlucore has recently appointed Fredrik Hellborg to strengthen sales within the diagnostics segment. Hellborg comes from Qiagen, where he was Market Development Manager for Clinical Genomics and Personalized healthcare. His focus is to establish Qlucore's software in the clinical cancer diagnostics market. He takes up the position on 15 August.

Fredrik Hellborg is a molecular biologist from Stockholm University with a doctoral thesis at Karolinska Institutet in experimental tumor biology. He has solid experience in sales and development within Life Sciences. He previously worked in sales at VWR, a large distributor of lab materials, helped build Pico Vitro's sales channels and worked in business development at Sophia Genetics, a company in sequence data analysis.

"Fredrik Hellborg will contribute to our increasing sales, partly through his network, partly through his experience in meeting the lab's needs in the field of cancer diagnostics – understanding what is in demand and how we best meet this," says Carl-Johan Ivarsson, Qlucore's CEO.

"Qlucore ensures that the research benefits the patients. This is where I want to be involved and contribute. What attracted me is that Qlucore provides the ability to interpret and visualize such large amounts of data, and that it is also done with a focus on analysts and treating doctors, says Fredrik Hellborg. He continues:

"There is huge potential in Qlucore. The fact that the software is modular is a strength, and the fact that Qlucore focused at an early stage on approval according to IVDR, the new regulatory framework for diagnostics, means that they have a big advantage once this potential is realized".

Datum 2022-08-15, kl 16:30
Källa MFN
SAVR är investeringsplattformen som utmanar branschen och gör det både enklare och roligare att investera. Betala aldrig för mycket! Alla aktier och ETF:er från 1 kr, och få upp till 50 % rabatt på alla fonder. Automatiskt courtage och samma enkla prismodell på alla marknader.
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet